Sign In
Buy ACXP
$1.75
-0.0500 (-2.78%)
At Close: Jun 03, 2026
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?
02:45pm, Wednesday, 11'th Mar 2026
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor react
Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial with ibezapolstat in patients wit
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
08:00am, Monday, 02'nd Feb 2026
STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
10:40am, Tuesday, 06'th Jan 2026
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the mo
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
10:11am, Wednesday, 12'th Nov 2025
Acurx Pharmaceuticals, Inc. ( ACXP ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secret
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
07:01am, Wednesday, 12'th Nov 2025
STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, MRSA,
Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC inhibitor, ibezapolstat (IBZ), has unique selective antibacterial activity in the gut which spares beneficial bile acid
STATEN ISLAND, N.Y. , Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
07:30am, Thursday, 09'th Oct 2025
STATEN ISLAND, N.Y. , Oct. 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small m
The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infection Re
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
10:13am, Tuesday, 12'th Aug 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants David P. Luci - Co-Founder, President, CEO, Corporate Secretary & Director R
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
07:01am, Tuesday, 12'th Aug 2025
STATEN ISLAND, N.Y. , Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
